Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Number of Patients with Dose-limiting Toxicities

A DLT is defined as an AE that meets at least one of the criteria listed in protocol, according to National Cancer Institute (NCI) common terminology criteria for AE (CTCAE) version 5.0, and is considered by the investigator to be clinically relevant and attributed to the study treatment during the first 28 days after the first dose of study treatment.

Time frame: Baseline up to 28 Days

Incidence of Adverse Events

Number of patients with adverse events (AEs) according to severity, seriousness, and relationship to study drug An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of patients who experience at least one AE will be presented.

Time frame: Baseline up to Approximately 24 Months

Number of Patients with Clinically Significant Laboratory Abnormalities

Number of patients with clinically significant change from baseline in laboratory abnormalities as characterized by type, frequency, severity (graded by CTCAE version 5.0) and timing.

Time frame: Baseline up to Approximately 24 Months

Number of Patients in Expansion Cohorts with Objective Responses

Objective Response Rate is defined as the proportion of patients who achieve a confirmed complete response (CR) or partial response (PR) according to RECIST v1.1

Time frame: Baseline up to approximately 24 months

Duration of Response for Patients in Expansion Cohorts

Duration of Response is defined as the time from the first documentation of objective response (CR or PR) that is subsequently confirmed per RECIST v1.1, to the time of the first documentation of objective tumor progression or to death due to any cause, whichever occurs first.

Time frame: Baseline up to approximately 24 months

Progression-free Survival for Patients in Expansion Cohorts

Progression-free survival is defined as the time from start of study treatment to the date of first documentation of objective tumor progression on or following study therapy per RECIST v1.1, or to death due to any cause, whichever comes first.

Time frame: Baseline up to approximately 24 months

Overall Survival for Patients in Combination Dose Expansion Cohorts

Overall survival is defined as the date from start of the study treatment to the date of death due to any cause.

Time frame: Up to approximately 48 months